| Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation A Pastò, C Bellio, G Pilotto, V Ciminale, M Silic-Benussi, G Guzzo, ... Oncotarget 5 (12), 4305, 2014 | 283 | 2014 |
| NOTCH3 signaling regulates MUSASHI-1 expression in metastatic colorectal cancer cells A Pastò, V Serafin, G Pilotto, C Lago, C Bellio, L Trusolino, A Bertotti, ... Cancer research 74 (7), 2106-2118, 2014 | 64 | 2014 |
| PARP inhibition induces enrichment of DNA repair–proficient CD133 and CD117 positive ovarian cancer stem cells C Bellio, C DiGloria, R Foster, K James, PA Konstantinopoulos, ... Molecular Cancer Research 17 (2), 431-445, 2019 | 50 | 2019 |
| Ovarian cancer stem cells: What progress have we made? LF Al-Alem, UM Pandya, AT Baker, C Bellio, BD Zarrella, J Clark, ... The international journal of biochemistry & cell biology 107, 92-103, 2019 | 49 | 2019 |
| Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells A Pastò, A Pagotto, G Pilotto, A De Paoli, GL De Salvo, A Baldoni, ... Oncotarget 8 (4), 6433, 2017 | 37 | 2017 |
| The Metabolic Inhibitor CPI-613 Negates Treatment Enrichment of Ovarian Cancer Stem Cells RBR Bellio C., DiGloria C., Spriggs D.R. ,Foster R., Growdon W.B. Cancers, 2019 | 25 | 2019 |
| Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau K Starbuck, L Al-Alem, DA Eavarone, SF Hernandez, C Bellio, ... Oncotarget 9 (33), 23289, 2018 | 24 | 2018 |
| GDF15 is an eribulin response biomarker also required for survival of DTP breast cancer cells C Bellio, M Emperador, P Castellano, A Gris-Oliver, F Canals, ... Cancers 14 (10), 2562, 2022 | 9 | 2022 |
| Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation. Oncotarget. 2014; 5: 4305-19 A Pasto, C Bellio, G Pilotto, V Ciminale, M Silic-Benussi, G Guzzo, ... PUBMED, 2010 | 5 | 2010 |
| Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer C Bellio, J Villanueva Annals of Translational Medicine 8 (14), 2020 | 3 | 2020 |
| Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer M Juliachs, M Pujals, C Bellio, N Meo-Evoli, JM Duran, E Zamora, ... Cancers 14 (16), 3858, 2022 | 2 | 2022 |
| Assessing the efficacy of the anti metabolic drug, CPI-613, for targeting of ovarian cancer stem cells C Bellio, R Foster, WB Growdon, BR Rueda Cancer Research 76 (14_Supplement), 2504-2504, 2016 | 1 | 2016 |
| RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer M Pujals, C Mayans, C Bellio, O Méndez, E Greco, R Fasani, ... Oncogene 42 (35), 2610-2628, 2023 | | 2023 |
| Epithelial-Mesenchymal plasticity mediates acquired resistance to eribulin in breast cancer C Bellio, E Zamora, C Saura, V Serra, BA Littlefield, J Villanueva European Journal of Cancer 174, S106-S107, 2022 | | 2022 |
| Abstract P069: GDF15 contributes to the maintenance of the drug-tolerant persister state in cells responding to eribulin C Bellio, M Emperador, E Zamora, V Serra, C Saura, BA Littlefield, ... Molecular Cancer Therapeutics 20 (12_Supplement), P069-P069, 2021 | | 2021 |
| GDF15 is a candidate circulating biomarker of eribulin response in breast cancer C Bellio, M Emperador, L Garrigós, E Zamora, C Saura, BA Littlefield, ... Cancer Research 81 (13_Supplement), 993-993, 2021 | | 2021 |
| Hitting the brakes on autophagy for overcoming acquired resistance in triple negative breast cancer J Villanueva Cardús, C Bellio AME Publishing Company, 2020 | | 2020 |
| Abstract A036: Identification of secretome-based eribulin biomarkers for breast cancer therapeutics C Bellio, JM Duran, O Méndez, N Meo-Evoli, C Salvans, L Garrigós, ... Molecular Cancer Therapeutics 18 (12_Supplement), A036-A036, 2019 | | 2019 |
| Abstract MIP-047: INHIBITION OF POLY ADP–RIBOSE POLYMERASE (PARP) IN OVARIAN CANCER CELLS ENRICHES FOR CD133 AND CD117 POSITIVE POPULATIONS C Bellio, R Foster, WB Growdon, P Konstantinopoulos, BR Rueda Clinical Cancer Research 23 (11_Supplement), MIP-047-MIP-047, 2017 | | 2017 |
| PARP Inhibitors for Treatment of Ovarian Cancer: The Downside of Good Intentions. C Bellio, R Foster, WB Growdon, BR Rueda REPRODUCTIVE SCIENCES 23, 179A-179A, 2016 | | 2016 |
